PC25377A Response to Office Action for USSN 10/669,819

REMARKS

Upon entry of the foregoing amendment, claims 1 to 3, and 10 to 13 are pending in the

application. Claims 4 to 9 and 14 to 16 are cancelled herein. Applicants respectfully reserve the

right to pursue the subject matter of these canceled claims in one or more future divisional or

continuation applications.

Applicants appreciate the Examiner's allowance of claims 1 to 3, 10 and 12 in the Office

Action of November 15, 2004.

Claims 11 and 13 are amended herein as recommended by the Examiner in the Office

Action of November 15, 2004. Applicants appreciate the Examiner's guidance in progressing this

application to allowance.

Applicants respectfully assert that this case is now in condition for Allowance and request

prompt notice thereof.

Respectfully submitted,

Date: February 14, 2005

Keith D. Hutchinson Attorney For Applicants

Registration No. 43,687

Agouron Pharmaceuticals, Inc./A Pfizer Company

Patent Department 10777 Science Center Drive

San Diego, California 92121 Phone: (858) 526-4608

Fax: (858) 678-8233